sb4

BMP signaling agonist sb4 (SB 4) is an agonist of benzoxazole bone morphogenetic protein (BMP) signaling (EC50 :74 nM)

SB405483 is a CRBN (cereblon) orthosteric ligand-binding enhancer that promotes the ubiquitination and proteasomal degradation of CRBN substrates (such as CK1α, Wee1, and IKZF1/3) by stabilizing the CRBN protein conformation and enhancing its binding affinity for substrates. SB405483 can be used in cancer research, such as in multiple myeloma and acute myeloid leukemia.

HSB401 is an orally active FLT3 inhibitor with IC50 values of 28, 5, 72, and 51 nM for FLT3-WT, FLT3-D835Y, FLT3-ITD-F691L, and FLT3-ITD, respectively. It downregulates the FLT3 signaling pathway, inducing cell cycle arrest and apoptosis. HSB401 does not inhibit c-KIT, which reduces the risk of bone marrow suppression. In the MV4-11 xenograft mouse model, HSB401 significantly suppresses tumor growth and is applicable for research in acute myeloid leukemia (AML).

SB-431542 is an inhibitor of ALK5/TGF-β type I Receptor (IC50=94 nM) and is selective. SB 431542 also has inhibitory activity against ALK4 and ALK7 but not other proteins. SB 431542 can be used for induced differentiation of stem cells.

Eltrombopag (SB-497115-GR), an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity, binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110).

Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active small-molecule, nonpeptide thrombopoietin receptor agonist that stimulates megakaryopoiesis. It binds to and activates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), promoting the proliferation and differentiation of megakaryocytic cells and enhancing platelet production.

SB-408124 Hydrochloride is a non-peptide OX1 receptor antagonist(Ki of 57 nM and 27 nM in both whole cell and membrane, respectively).

SB-423557 is an orally active antagonist of the calcium-sensing receptor (CaR), demonstrating an IC50 of 520 nM.

SB-423562 is a calcium-sensing receptor (CaSR) antagonist and can be used in studies about osteoporosis.

Odiparcil is an orally active beta-d-thioxyloside analog. Odiparcil is an indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II). It also has an antithrombotic activity associated with a reduced risk of adverse bleeding events.

SB-405483 is a CRBN (Cereblon) positive modulator that facilitates the degradation of CRBN substrates, which include CK1α, Wee1, and IKZF1/3. Furthermore, SB-405483 stabilizes CRBN and reduces its own ubiquitination levels. This compound is applicable in cancer research, such as in studies on multiple myeloma and acute myeloid leukemia.

SB 452533 is an antagonist of the vanilloid receptor 1(pKb: 7.8).

SB-414796 is a selective antagonist of the dopamine D3 receptor.

SB-429201 is an effective, selective inhibitor of HDAC1.

SB-423562 is a calcium-sensing receptor antagonist.

SB-436811 is an antagonist of human urotensin-II receptor.

SB 414240 is a bioactive chemical.

SB-410220 is a bioactive chemical.

(E/Z)-Eltrombopag-13C4 is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13C labeled. Z-Eltrombopag is a thrombopoietin (TPO) receptor agonist developed for certain conditions that lead to thrombocytopenia.

Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V, exhibiting high affinity with Ki values of 41 pM, 68 pM, and 53 pM, respectively. It effectively inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. In vitro studies confirm its inhibitory effect on bone resorption in human tissue, and in vivo studies on cynomolgus monkeys validate its efficacy in reducing bone resorption.

Darapladib (SB-480848) is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with an IC50 value of 0.25 nM, which can exert cardiovascular protective effects [1,3].

SB408124 is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and 27 nM in both whole cell and membrane, respectively, exhibits 50-fold selectivity over OX2 receptor.

SB 415286 is a potent GSK3α inhibitor with IC50/Ki of 78 nM/31 nM with equally effective inhibition of GSK-3β.

SB-435495 is an orally active, selective and potent Lp-PLA2 inhibitor (IC50 of 0.06 nM) for the study of autoimmune uveitis and atherosclerosis.